Green Enantioselective Halogenation for Drug Discovery and Manufacture
The aim of this project is to bring together subject matter experts from the academic and non-academic sectors to develop and exemplify the use of new catalysts and new green reactions to manufacture important halogenated compound...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PHOTO-FLUOR
Enantioselective Carbon Fluorine Bond Formation A Molecular...
170K€
Cerrado
ElectronsOnRun
Electrochemical fluorination under microflow conditions
192K€
Cerrado
ELECTRO-ASYMMETRIC
Electrochemical stereoselective radical cascades for accessi...
Cerrado
SAF2010-20822-C02-02
DISEÑO Y DESARROLLO DE PROCESOS ENANTIOSELECTIVOS CATALIZADO...
36K€
Cerrado
CTQ2017-84900-P
REACCIONES DE ADICION ENANTIOSELECTIVAS MEDIANTE SISTEMAS MU...
115K€
Cerrado
HaloCat
Elemental Halogen Free Reversible Construction and Deconstru...
203K€
Cerrado
Información proyecto GreenX4Drug
Duración del proyecto: 61 meses
Fecha Inicio: 2018-11-09
Fecha Fin: 2023-12-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The aim of this project is to bring together subject matter experts from the academic and non-academic sectors to develop and exemplify the use of new catalysts and new green reactions to manufacture important halogenated compounds that could be used in drug discovery and drug production.
In order to achieve this objective the proposal brings together 3 partners with complementary skills:
University of Naples (UNINA): expertise in medicinal chemistry and drug discovery.
KelAda Pharmachem: expertise in green chemistry, chemical batch process development and scale-up.
UCO: expertise in process engineering of continuous flow processes.
We have broken this proposal into the following separate technical Work Packages:
WP1: Preparation of new catalysts for efficient desymmetrization [WP Leader: UNINA].
WP2: Development of enantiospecific halogenation including Fluorination. [WP Leader: Kelada Pharmachem].
WP3 Drug Candidate, library creation & in vitro testing. [WP Leader: Kelada Pharmachem]
WP4 Development of flow variant and scale-up.[WP Leader: UCO}
The above WP's will be undertaken via a series of interlinked secondment of researchers between the consortium partners and will be complemented by a series of training and other initiatives to facilitate interdisciplinary and inter-sectoral knowledge sharing and exchange.